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Influence of aluminum on mineralization during matrix—induced bone
development. A model of de novo mineralization employing matrix—in-
duced endochrondral bone formation in rats was used to study the
short—term effects of aluminum on the deposition of calcium and
phosphate in vivo. In experiments where systemic aluminum concen-
trations were elevated, the cellular processes associated with bone
development appeared to be normal, if somewhat delayed, however
precipitation of the mineral phase was prevented. This suggests a
primary direct physical chemical effect of aluminum in vivo on calcifi-
cation, as suggested by in vitro studies which demonstrate that alumi-
num is a potent inhibitor of calcium phosphate precipitation. Aluminum
salts implanted locally with the matrix appeared to be toxic to the
cellular processes leading to chondrogenesis and osteogenesis.
Accumulation of aluminum (Al) in bone and the osteomalacia
that develops has been described in chronic or maintenance
dialyzed patients, and a direct relationship between the Al
deposited and the histomorphometric changes have been re-
ported [1—3]. Osteomalacia, osteitis fibrosa and mixed lesions
were found by Hodsman et al in 59 hemodialyzed patients in
whom iliac crest biopsies were performed. The highest Al
content was present in the bone of the patients with
osteomalacia [2], and Al was found to be deposited at the
mineralization front of the osteomalacic bone [4]. Orally admin-
istered Al hydroxide was partially absorbed and also could
induce bone changes with renal insufficiency [5, 6].
In animal studies, prolonged administration of intraperitoneal
Al in rats was shown to result in an impaired mineralization of
the growth plate [I], and administration of Al during four weeks
induced a reduction of total bone and matrix formation, as well
as of periosteal bone and matrix formation in rats with a normal
renal function [7]. In addition to a direct effect of Al on bone,
other studies showed systemic effects such as phosphate deple-
tion, increase of serum calcium levels and a decrease of renal
function [8, 91. In culture, low concentrations of Al stimulated
bone phosphatase activities in three-day-old calvaria, whereas
at higher concentrations an inhibition was observed [10].
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A previous report suggested that the impaired mineralization
could be due to a direct physical chemical effect of Al ion on the
precipitation of calcium phosphate [11]. This was suggested
based upon the results of in vitro studies [12, 13]. The present
study was undertaken to examine the effects of aluminum
treatment on de novo mineralization employing the matrix—in-
duced endochondral bone development system [14—16] during a
short-term exposure in rats. This in vivo system allowed a study
of the effect of Al on the calcification process to be uncomplicated
by previous mineralization that had occurred as in long bone. The
results demonstrate that Al, indeed, had pronounced inhibitory
effects on mineralization, and these effects could be dissociated
from the cellular parameters and alkaline phosphatase activity
during bone development.
Methods
Demineralized bone matrix prepared from rat diaphysis was
implanted subcutaneously into bilateral sites in the thoracic
region of 28-day-old (110 to 120 g) male Long—Evans strain as
described earlier [14]. The day of implantation was designated
as day 0. On assigned days the subcutaneous button-like
compact plaques were dissected, freed of adherent tissues and
weighed. Representative samples were fixed in Bouins fluid for
histology and 1 .tm sections were stained with toludine blue.
Systemic ejfrct of Al
Two groups of 18 rats each were studied. The experimental
group received intraperitoneal injections of aluminum chloride
in normal saline vehicle while the control group received only
vehicle. The experimental group received a priming dose of 1
mg elemental Al/day/rat for one week before the demineralized
bone matrix was implanted. Afterwards, the dose was increased
to 2 mg elemental Al/day/rat for 10 and 14 days, respectively.
This dose was chosen after preliminary experiments with 0.5,
1.0, and 2.0 mg doses showed maximal effect on de novo
mineralization with no apparent toxicity. On day 10 and 14 after
the implantation of demineralized matrix, 12 rats each (6 control
and 6 experimental) were sacrificed. At the time of sacrifice,
blood was collected by cardiac puncture 24 hr after the last
injection for serum Al analysis. The additional animals were
used for histological examination.
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Table 1. Serum aluminum concentrations for control and
experimental animals
Day after implantation
10 14
Control p.g/liter 9.0 2.0 13.0 3.0
Experimental jsg/liter 97 14* 207 54*
Values represent the mean SE (6 observations). *D < 0.001 vs. C
Local effects of Al
The local effects of Al were studied by physically mixing the
aluminum salt (as the chloride) with the demineralized bone
matrix. Less than 1/10 of the total cumulative dose of the
systemic experiments (that is, 2 mg elemental AL/rat) was mixed
with demineralized bone matrix before implantation. Two
groups of eight rats each were studied. The experimental group
of rats were implanted with the demineralized matrix containing
aluminum whereas the control group was implanted with the
matrix containing the same amount of sodium chloride. The
animals were sacrificed on day 10 (cartilage mineralization and
early bone formation) and on day 14 (bone mineralization).
Neither systemic or local administration of Al resulted in a
significant difference in body wt compared to control animals.
All animals appeared healthy.
Alkaline phosphatase and calcium uptake
On the assigned days, the dissected plaques were homoge-
nized in ice-cold 0.15 M sodium chloride containing 2 mM
sodium bicarbonate and centrifuged at 20,000 g for 15 mm at 4°.
Alkaline phosphatase activity in the supernatent was deter-
mined as described earlier [14]. The presence of increased
alkaline phosphatase activity (0.1 M sodium barbital buffer, pH
9.3) indicated the cellular events associated with bone forma-
tion were then occurring. The saline insoluble sediment con-
taining the mineral fraction was washed twice with 10 muter
Tris-HCI (0.005 M) and the pellets stirred for 1 hr. After
centrifugation at 3000 g the supernatents were discarded. The
mineral phase was dissolved in 10 mliter 0.5 M HCI by stirring
overnight at 25°C. After centrifugation at 3000 g the superna-
tants were utilized for calcium analysis. Calcium was deter-
mined by conventional atomic absorption spectroscopy. Serum
Al analysis was done by the method of Leung and Henderson
[181. Calcium uptake was calculated as pg/mg of wet wt of
tissue whereas alkaline phosphatase activity was expressed as
units/mg protein. Plasma calcium levels were also measured on
all animals. The statistical significance was evaluated by the
Students (test.
Results
Serum aluminum levels for control and experimental animals
after 10 and 14 days of intraperitoneal administration are given
in Table 1. As expected, Al levels were significantly higher in
the experimental animals as compared to the controls. There
were no differences between the plasma calcium levels in the
two groups of animals.
The effects of intraperitoneal administration of Al on bone
formation and mineralization are summarized in Table 2. At 10
Table 2. Effects of intraperitoneal aluminum on alkaline phosphatase
and calcium content of implants.
Control Experimental
Alkaline phosphatase
Units/mg protein 2.07 0.429 1.48 0.56*
Day 10
Calcium, jsg/tng tissue 2.232 0.776 0.184 0.072**
Alkaline phosphatase
Units/mg protein 3.79 1.05 3.88 1.83
Day 14
Calcium, jig/mg tissue 19.82 6.33 0.367 .38**
Values represent the mean SD (12 observations). Symbols are:
<0.01; ** < .001.
Table 3. Effects of local aluminum on alkaline phosphatase and
calcium content of implants.
Control Experimental
Alkaline Phosphatase
Units/mg tissue 3.94 1.66 0.69 0.23*
Day 10
Calcium, pg/mg tissue 2.32 0.75 0.27 0.08*
Alkaline Phosphatase
Units/mg protein 5.43 1.16 1.05 0.23*
Day 14
Calcium, ,sg/mg tissue 19.95 5.49 0.68 0.28*
Values represent the mean SD (6 observations). *p < 0.001 vs. C
days alkaline phosphatase was decreased in the experimental
animals, however at day 14 alkaline phosphatase activity was
restored to normal. Calcium uptake by the plaques was essen-
tially completely inhibited on both day 10 and 14.
The local effect of Al is summarized in Table 3. Alkaline
phosphatase activity was significantly decreased at day 10 and
14. Calcium uptake was strongly inhibited in the extracted
samples at days 10 and 14. Plasma calcium levels were not
affected by the local administration of aluminum, however.
The histological findings are shown in Figures 1 and 2. The
plaques dissected from the control animals on day 10 (not
shown) exhibited hypertrophic chondrocytes, vascular invasion
and early osteoblasts. The bone matrix formation and osteo-
blastic activity were normal on day 14 (Fig. 1). In the animals
which received Al intraperitoneally for 10 days, no difference
from control rats was seen and it would appear that
chondrogenesis was normal. Mineralization, however, was
completely inhibited. The presence of chondrocytes at day 14
suggested that the overall mineralization process was somewhat
delayed in the presence of elevated serum Al even though the
biochemical marker of calcification, alkaline phosphatase, (Ta-
ble 2), was normal. The deposition of calcium and phosphate
was again completely inhibited in the day 14 plaques.
In the plaques dissected from the animals where the Al was
implanted with the powder, there was no evidence of chondro-
genesis or osteogenesis (Fig. 2). The implants consisted of
fibroblasts and mesenchymal cells on both days 10 (not shown)
and 14.
In neither the systemic nor locally implanted aluminum-treated
animals was there a significant difference in the histology of tibial
bones, as expected, for these short term experiments.
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Fig. I. Photomicrographsofhistological sections of subcutaneous implants obtained from rats on day 14 ( x 220). A. Control. the implant consists
ofseveral osteoblasts and evidence of bone formation. B. Al treated rats (systemic dose). The implant exhibits hyperthophic chondrocytes and
osteobiasts.
Discussion
The early effects of Al on bone growth, bone formation,
mineralization and resorption were reported by Goodman et al,
with a 20% reduction in bone formation in rats with normal
renal function and a decrease of 40% in nephrectomized animals
191. The Al concentration in bone has a direct relationship to the
histological findings, suggesting a local effect in addition to the
systemic one. Evidence of osteomalacia related to bone Al
deposits was shown also in patients receiving total parenteral
nutrition [191. Addition of Al chloride to the culture media of
embryonic chick bone caused an inhibitory effect on mineral-
ization and a decreased uptake of radioealeium [20], 'l'he
duration of Al administration in the present investigation was a
short one, demonstrating the effect already after 10 and 14 days.
Demineralized bone matrix when implanted subcutaneously
into allogenic rats induces an invarient sequence of events
resulting in de novo cartilage, bone and bone marrow formation
[14, 17]. The results of the present study show that aluminum
has a strong inhibitory effect when implanted together with the
demineralized bone powder, as well as when administered
intraperitoneally, confirming a direct effect on bone.
The effect of Al on dc novo calcification, when implanted locally
with the demineralized powder, would appear to be due to a direct
toxic effect on the cellular processes leading to mineralization.
Both the biochemical and histological parameters showed gross
abnormalities in the plaques of the aluminum-treated animals.
In contrast, the animals treated systemically with Al ap-
peared to be not remarkably different from control animals,
except that serum Al concentrations were elevated and the
deposition of calcium and phosphate in the mineral phase of
bone was prevented. This would tend to confirm the earlier
suggestion that Al may he adversely affecting mineralization in
aluminum-induced osteomalacia via a direct physical chemical
effect of Al on bone mineral phases [II]. The results reported
here show that chondrogenesis (day 10 plaques) appeared to
proceed normally in systemic aluminum-treated animals, ex-
cept for a slight reduction in alkaline phosphatase activity.
However, deposition of mineral phase did not occur. Similarly,
day 14 plaques showed normal alkaline phosphatase activity
suggesting normal osteogenic activity, and again, mineraliza-
tion did not occur. Although the primary effect of Al on de novo
calcification in this system appeared to be the physical chemical
prevention of the precipitation of the mineral phase, histological
examination of the developing plaques appears to suggest that
elevated Al concentrations in serum also delay the cellular
aspects of osteogenesis.
It should be noted that the observed results could also be due
to imbalances caused by systemic Al in the levels of other
factors, such as parathyroid hormone, associated with bone
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Fig. 2. Photomicrographsof histological sections of subcutaneous implants obtained from rats on day 14 (x 220). A. Control. The implant consists
of newly formed bone. B. Al treated (local administration). The implant shows marked inhibition and consists of fibroblasts and particles of the
implanted bone matrix.
formation. This was not felt to be the case in the present study
because of the short duration of the experiments, the relatively
low doses of Al involved, and the lack of any histological
evidence that bone damage occurred. In support of this was the
observation that the "local" administration of Al produced a
much greater impairment to de novo bone formation than the
"systemic" administration, even though less than one tenth of
the total Al was available for circulation. Systemic Al concen-
trations for the "local" experiments were not measured, how-
ever, and other complicating factors cannot be ruled out. The
important consideration would seem to be that small amounts of
Al appear to be capable of preventing the de novo deposition of
mineral phase in the model system under study here before any
effect on existing bone could be detected. This further suggests
a specific effect on the initial formation of the inorganic phase.
As shown earlier [13], the systemic concentrations of Al at-
tained in this study (3.6 tM, day 10; 7.6 sM, day 14), especially
in the presence of physiological citrate concentrations, would
have a marked effect on the rate of crystallization of calcium
phosphate and could seriously affect the remineralization of
bone given a sufficient amount of time.
In summary, the results of this study suggest that moderately
elevated concentrations of Al appear to have a selective,
physical chemical effect on the deposition of calcium phos-
phate, largely disassociated from any biochemical or cellular
event, as determined in an in vivo model of de novo bone
formation. Higher local concentrations of Al, however, appear
to have marked effects on all parameters associated with the
mineralization process in this model.
Reprint requests to John L. Meyer, Ph.D., Division of Research
Grants, National Institutes of Health, Westwood Building, Room 337,
Bethesda, Matyland 20892.
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